MicroRNA-1 suppresses proliferation, migration and invasion by targeting Notch2 in esophageal squamous cell carcinoma

Wenzhi Liu1, Mengkao Li4, Xiangming Chen1, Shan Zhu5, Hailong Shi1, Dawei Zhang6, Cheng Cheng7 & Baosheng Li2,3

MicroRNAs play an important role in the migration and invasion of tumors, and lower expression of microRNA-1 (miR-1) has been proven in a variety of malignant tumors, including esophageal squamous cell carcinoma (ESCC). In this study, we found that miR-1 expression levels in tumor tissues and preoperative serum from esophageal carcinoma patients were lower than those in non-tumorous tissues and healthy volunteers. miR-1 expression in tissues and plasma was closely related to invasion, lymph node metastasis and TNM staging. Additionally, miR-1 expression levels in tissues and plasma were positively correlated. miR-1 inhibited cell proliferation, migration and invasion. Overexpression of miR-1 in ESCC cells reduced Notch2 protein but not mRNA levels, whereas suppression of miR-1 led to an increase in Notch2 protein but not mRNA levels. A dual-luciferase experiment validated that Notch2 was a direct target of miR-1. Introducing Notch2 mRNA into cells over-expressing miR-1 partially abrogated the effects of miR-1 on migration and invasion. Further studies verified that miR-1 regulates EMT signalling pathways directly through Notch2. Therefore, these results confirm that, as a tumor suppressor gene, miR-1 may be a potential tumor marker for the early diagnosis of ESCC and a new drug target.

Esophageal cancer is the world's eighth most malignant tumor and has a 5-year-survival rate of less than 15%1. ESCC, which is characterized by invasiveness, recurrence and metastasis, is the most common pathological type of esophageal cancer in East Asia. Due to the lack of typical clinical symptoms and effective techniques for early diagnosis, esophageal cancer is typically at a late stage when diagnosed. Therefore, it is very important to understand the mechanisms of the occurrence and development of esophageal cancer at the molecular level and to explore diagnostic options and effective treatment targets for early diagnosis and treatment of esophageal cancer.

MicroRNAs (miRNAs) are a class of non-coding RNAs that are approximately 19–22 nucleotides in length and play multiple roles by binding to the 3′-untranslated region (3′-UTR) of target genes2,3. More than 60% of human protein-coding genes are expected to be regulated by miRNAs4, which are involved in the development and progression of malignant tumors by acting on different target genes5,6. These genes play important roles in regulating cell differentiation, proliferation, invasion, apoptosis and angiogenesis7–9. Our microarray analysis showed that the expression levels of miR-1 in ESCC tissues were 0.18 times higher than in normal tissue and that miR-1 is a tumor suppressor. In the previous study, miR-1 is downregulated in ESCC10, which occurs through the

1Department of Clinical Oncology, Taian City Central Hospital, Taian, Shandong Province, P. R. China. 2Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong Province, P. R. China. 3Shandong Academy of Medical Sciences, Jinan, Shandong Province, P. R. China. 4Department of Neurosurgery, Taian City Central Hospital, Taian, Shandong Province, P. R. China. 5Department of Oncology, Shandong Provincial Western Hospital, Jinan, Shandong Province, P. R. China. 6Trauma orthopedics ward, Zibo Central Hospital, Zibo, Shandong Province, P. R. China. 7Cardiovascular department ward, Zibo Central Hospital, Zibo, Shandong Province, P. R. China. Correspondence and requests for materials should be addressed to B.L. (email: baoshli1963@163.com)
repression of MET, cyclin D1 and CDK4 expression, and indicates a novel strategy for the diagnosis and treatment of ESCC. However, the key target gene of miR-1 in ESCC is still undefined and requires further exploration.

The Notch signalling pathway is a highly conserved pathway that affects cell proliferation, differentiation, apoptosis, and adhesion and is closely related to embryonic development, angiogenesis and tumor formation. The Notch signalling pathway is composed of Notch receptors, DSL protein ligands and intracellular effector molecules. Mammalian Notch receptors can be divided into four types: Notch1, Notch2, Notch3 and Notch4. Notch2 plays an important role in the development of various tumors, promoting tumor proliferation and reducing the sensitivity of tumors to 5-fluorouracil in hepatocellular carcinoma. In non-small cell lung cancer, high Notch2 mRNA expression predicted better overall survival in lung adenocarcinoma. Wang found that overexpression of Notch2 in ESCC is closely related to overall survival (OS) and progression-free survival (PFS) and that its expression could serve as a biomarker to identify individuals with poor prognostic potential. However, current research rarely addresses miRNAs and Notch2 interactions in ESCC.

In this study, we examined the expression of miR-1 in ESCC tissues and plasma and up-regulated or down-regulated miR-1 expression through cell transfection. We observed the effect of miR-1 on ESCC cell proliferation, cell migration and invasion, searched for the direct target gene of miR-1, and explored the mechanism of miR-1 in the pathogenesis of ESCC. The results provide a new theoretical basis for diagnosing and treating ESCC.

Results

miR-1 is down-regulated in ESCC tissue and plasma. Expression of miR-1 in 69 ESCC tissues and corresponding adjacent normal tissues was detected by quantitative real-time PCR (qRT-PCR). The expression level of miR-1 in ESCC tissues was significantly lower than that in adjacent normal tissues (3.004 ± 0.185 vs. 12.886 ± 6.49; p < 0.05) (Fig. 1A). As shown in Table 1, we found that the miR-1 level in tissues was closely related to invasion, lymph node metastasis and TNM staging (p < 0.05). At the same time, we also detected the expression of miR-1 in preoperative plasma from 69 patients and in plasma from 33 healthy volunteers. The miR-1 level in tumor patients was significantly lower than that in healthy volunteers (0.810 ± 0.071 vs. 3.477 ± 0.427; p < 0.01) (Fig. 1B). As shown in Table 1, the expression of miR-1 in plasma was closely related to invasion, lymph node metastasis and TNM staging (p < 0.05). Pearson’s correlation test showed that the level of miR-1 in tumor tissue was positively correlated with that in plasma (r = 0.622, p < 0.01, Fig. 1C).

miR-1 inhibits cell proliferation, migration and invasion. We detected the miR-1 level by qRT-PCR in six ESCC cell lines (Fig. 1D). TE-1 cells were found to have the highest level of miR-1, and KYSE410 cells expressed the lowest level. Therefore, these two cell lines were used for functional testing. TE-1 and KYSE410 cells were transfected with miR-1 mimics, negative control (NC), miR-1 inhibitor, and inhibitor NC. As shown in Fig. 1E,F, using qRT-PCR, we found that the miR-1 level in the miR-1 mimics group was significantly higher than that in the NC group in both TE-1 and KYSE410 cells. In addition, miR-1 expression in the miR-1 inhibitor group was significantly lower than that of cells in the inhibitor NC group.

CCK-8 experiments were used to assess the proliferation of ESCC cells at 24, 48, and 72 h after transfection. As shown in Fig. 2A,B, the proliferation of cells in the miR-1 mimics group was significantly lower than that in the NC group for both of TE-1 and KYSE410 cells at 72 h (p < 0.05). In addition, the proliferation ability of cells in the miR-1 inhibitor group was significantly higher than that of cells in the inhibitor NC group (p < 0.05). These results show that miR-1 can inhibit the proliferation of ESCC cells.

As shown in Fig. 2C,D, the migration and invasion of TE-1 and KYSE410 cells in the miR-1 mimics group decreased significantly compared with that in the NC group (p < 0.01), while the migration and invasion of cells in the miR-1 inhibitor group increased significantly compared with the inhibitor NC group (p < 0.01). Therefore, miR-1 can inhibit the migration and invasion of ESCC cells.

miR-1 directly regulates Notch2 expression by targeting its 3′-UTR. miRanda, miRDB, miRWalk, and TargetScan were used to predict the potential target gene of miR-1. As shown in Fig. 3A, as a result of the intersection of the four bioinformatics software programs, we predicted that Notch2 may be the target gene for miR-1. In Fig. 3B, we can see that the relationship between Notch2 and miR-1 3′-UTR regions followed the base complementary pairing principle. As shown in Fig. 3C (the dual-luciferase reporter assay), we found that luciferase activity in miR-1 mimic was significantly lower than that of cells transfected NC in the Notch2–3′UTR-WT group (**p < 0.01), but that was no significant difference in the Notch2–3′UTR-MT group, so miR-1 mimic had no effect on Notch2–3′UTR-MT (p > 0.05). Luciferase activity was significantly higher in miR-1 inhibitor than that for cells transfected with inhibitor NC in the Notch2–3′UTR-WT group (**p < 0.01). However, luciferase activity showed no significant difference in the Notch2–3′UTR-MT group (p > 0.05). These observations demonstrate that miR-1 directly regulates Notch2 expression by targeting its 3′-UTR.

The mechanism of miR-1 regulation of Notch2 was further investigated by assessing expression of miR-1 in transfected TE-1 and KYSE410 cells. Expression of Notch2 protein in the miR-1 mimics group was lower than that in the NC group (Fig. 4A,B), but there was no significant difference in Notch2 mRNA expression (Fig. 4C). Expression of Notch2 protein in the miR-1 inhibitor group was higher than that in the NC group (Fig. 4A,B), but there was no significant difference in Notch2 mRNA expression (Fig. 4C). In ESCC tissue, we found that miR-1 was negatively correlated with Notch2 protein based on a Pearson correlation analysis (r = −0.713, p < 0.01) (Fig. 4D), but not with Notch2 mRNA (r = −0.202, p = 0.097) (Fig. 4E). Thus, these results demonstrate that miR-1 post-transcriptionally regulates Notch2 expression.

Notch2 expression attenuates the inhibitory effects of miR-1. We explored the effects of Notch2 on the migration and invasion of ESCC cells. Notch2 was found to play an oncogenic role and increased the migration and invasion of ESCC cells. To further explore the functional relationship between miR-1 and Notch2, we
designed a Notch2 vector and co-transfected TE-1 and KYSE410 cells with this vector and miR-1 mimics. It was found that the Notch2 vector attenuated the miR-1 inhibitory effect of miR-1 mimics on Notch2 protein in tumor cells (Fig. 5A,B). The Notch2 vector attenuated the inhibitory effect of miR-1 mimics on migration and invasion (Fig. 5C,D). Thus, miR-1 regulates ESCC cell migration and invasion by acting on Notch2.

miR-1 regulates EMT signalling. To understand whether miR-1 can regulate epithelial-mesenchymal transition (EMT) signalling, we performed transfection experiments to increase or decrease the expression level of miR-1 to observe changes in classical factors, such as E-cadherin, Vimentin and TGF-β1, in the EMT pathway. miR-1 mimics increased E-cadherin protein, while down-regulating the expression of Vimentin and TGF-β1 protein (Fig. 6A,B). miR-1 inhibitor decreased the expression of E-cadherin protein, while Vimentin and TGF-β1 protein was up-regulated (p < 0.01) (Fig. 6A,B). Thus, we speculate that miR-1 can regulate EMT signalling.
miRNAs exert a biological function by targeting the 3'-UTR region of genes. Because this region regulates subcellular localization, nuclear transport and stabilizes transcripts, miRNAs play an important role in cells. A variety of miRNAs are abnormally expressed in ESCC patients, and their expression is closely related to clinical features such as pathological type, differentiation, lymph node metastasis, TNM staging, prognosis and chemotherapy sensitivity. Study of the pathogenesis of miRNAs and ESCC not only provides new clues for molecular markers of ESCC but also provides a useful way to find new drug targets for ESCC.

miR-1 is an important miRNA that acts as a tumor suppressor gene in a variety of malignant tumors. miR-1 is involved in post-transcriptional regulation of crucial tumor-associated genes and is a promising target for anticancer therapy. Re-expression of miR-1 inhibited cancer cell proliferation, promoted apoptosis, and reversed drug resistance in cancer both in vitro and in vivo. Overexpression of miR-1 in prostate cells led to growth inhibition and down-regulation of genes in pathways that regulate cell cycle progression, mitosis, and DNA replication/repair and participate in dynamics. miR-1 acted as a tumor suppressor in prostate cancer by affecting a variety of cancer-related processes and by inhibiting cell proliferation and movement. miR-1 acted as a tumor suppressor in prostate cancer by affecting a variety of cancer-related processes and by inhibiting cell proliferation and movement.

We confirmed low expression of miR-1 in ESCC tumor tissue and first detected low expression of miR-1 in preoperative ESCC plasma, and the miR-1 levels in plasma and tissues were associated with invasion, lymph node metastasis and TNM staging. In addition, miR-1 expression in tissues was consistent with that in plasma.

Table 1. The relationship between the levels of miR-1 in tissue and plasma and clinicopathologic characteristics of ESCC patients (*indicates p < 0.05, **indicates p < 0.01).
Therefore, miR-1 may be a potential tumor marker for diagnosis of ESCC. miR-1 is also an important factor in the diagnosis and prognosis of breast cancer and liver cancer. Circulating miR-1 has the potential to be a new biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.

Figure 2. miR-1 inhibits proliferation, migration and invasion in TE-1 and KYSE410 cells. (A,B) The proliferation ability of cells in the miR-1 mimics group was lower than that of cells in the NC group (*p < 0.05). The proliferation of cells in the miR-1 inhibitor group was significantly higher than that in the NC group (*p < 0.05). (C,E) The migration and invasion ability of TE-1 cells were different from those of the NC group. Scale bars indicate 100 μm (**p < 0.01). (D,F) The migration and invasion ability of transfected KYSE410 cells were significantly different from those of the NC group. Scale bars indicate 100 μm (**p < 0.01).
We further investigated the function of miR-1 in two representative cell lines: TE-1 and KYSE410 cells. We transfected mimics or inhibitor into cells, thus increasing or decreasing the miR-1 level. An increase in miR-1 was found to inhibit the proliferation, migration and invasion of TE-1 and KYSE410 cells, while decreased miR-1 expression enhanced the proliferation, migration and invasion of tumor cells. In osteosarcoma, miR-1 exerts an inhibitory effect on cell proliferation and invasion by acting on VEGFA30. miR-1 overexpression promoted apoptosis by targeting G6PD in cervical cancer cells 31.

The relationship between miRNA and target genes is complex. The same miRNA typically regulates multiple target genes32,33, and multiple miRNAs can act on the same target gene34,35. In recent years, the active involvement of miR-1 in regulation of various target genes has been investigated. miR-1 expression levels were found to be significantly correlated with tumor invasion and advanced clinical stage36. miR-1 suppresses cell proliferation, invasive-ness, metastasis, and ESCC progression by binding to its target genes LASP1 and TAGLN226. To further elucidate the carcinogenesis mechanism of miR-1, we first took advantage of bioinformatics software, combined with tumor invasion and metastasis related genes in ESCC, and selected Notch2 as the potential target gene. As a major receptor in the Notch pathway, Notch2 plays an important role in the development and progression of acute myeloid leukaemia, bladder cancer, gastric cancers, ESCC and other malignant tumors14,37–39. We found that miR-1 can down-regulate Notch2 protein in tumor cells, but no change in Notch2 mRNA was observed. The miR-1 in tumor tissue was correlated with Notch2 protein level, but not with Notch2 mRNA. We found that Notch2–3′UTR-WT could significantly decrease the luciferase activity of miR-1-overexpressing ESCC cells and increase the luciferase activity of ESCC cells with low expression of miR-1. We found that Notch2 vector was able to attenuate the inhibitory effect of miR-1 mimics on Notch2 protein, migration and invasion in ESCC cells. It was further verified that miR-1 inhibited growth and invasion of tumors by regulating Notch2 at the post-transcriptional level.

EMT refers to morphological changes that occur in cells during transition from an epithelial to an interstitial cell phenotype. Epithelial cells lose cell polarity and intercellular adhesion and access migration and invasion ability, developing mesenchymal cell morphology and characteristics. EMT plays an important role in tumor invasion and metastasis. A variety of signalling pathways are involved in EMT in tumor cells, such as the Notch, Wnt, TGF-β, NF-κB, and other pathways. This study found that miR-1 increased E-cadherin protein and down-regulated the expression of Vimentin and TGF-β1 protein. Therefore, we hypothesized that miR-1 regulates EMT signalling directly through Notch2.

The expression of miR-1 in ESCC tissues and peripheral plasma was significantly decreased, and its expression level was closely related to invasion, lymph node metastasis and TNM stage. As a tumor suppressor gene, miR-1 inhibited ESCC cell proliferation, migration and invasion. It can inhibit the development and progression of
ESCC by directly regulating the expression of Notch2 protein. miR-1 can be used as a potential tumor marker for early diagnosis of ESCC and a new drug target.

**Materials and Methods**

**Clinical Specimens.** A total of 69 patients were first diagnosed with ESCC at Taian Central Hospital (Taian, Shandong, China) from June 2014 to May 2016. Preoperative patients did not receive radiotherapy, chemotherapy, biological therapy, or traditional Chinese medicine treatments. Peripheral blood (2 ml) was collected from each patient before surgery. ESCC tissues, adjacent normal tissues from the same patients and plasma samples from 33 healthy volunteers were also collected. This study was approved by the Ethics Committee of Taian Central Hospital, and each patient signed an informed consent. The study was based on the Declaration of Helsinki.

**Cell Culture.** The ECA109, TE-1, TE-8, and TE-13 cell lines were donated by the Central Laboratory of Shandong Cancer Hospital Affiliated to Shandong University (Jinan, Shandong, China). The KYSE410 and EC9706 cell lines were purchased from the Shanghai Cell Bank of Chinese Academy of Medical Sciences (Shanghai, China). Six ESCC cell lines were cultured in RPMI-1640 medium (HyClone, Logan, Utah, USA)
containing 10% foetal bovine serum (FBS, HyClone) and 0.2% penicillin streptomycin (Invitrogen, Carlsbad, CA, USA). All cells were cultured in a 5% CO₂ incubation chamber at 37 °C.

**RNA extraction, reverse transcription and qRT-PCR.** The miRNeasy Mini Kit (Qiagen, Duesseldorf, Nordrhein-Westfalen, Germany) was used to extract the total RNA from ESCC tissues, adjacent normal tissues and ESCC cells. The miRNeasy Serum/Plasma Kit (Qiagen) was used to extract the total RNA from serum collected from ESCC patients before surgery and from healthy volunteers. RNA integrity was detected by formaldehyde.

Figure 5. Notch2 expression attenuates the inhibitory effects of miR-1. (A, B) Notch2 vector attenuated the inhibitory effects of miR-1 mimics on Notch2 protein (***p < 0.01). (C, D) Notch2 vector attenuated the inhibitory effect of miR-1 mimics on tumour cell migration and invasion (***p < 0.01).
denaturing agarose gel electrophoresis. The purity of the total RNA was detected by the A260/280 ratio. The miScript II RT Kit (Qiagen) was applied for reverse transcription. A miScript SYBR Green PCR Kit (Qiagen) was used to perform PCR, and U6 was used as the internal reference to normalize the target gene levels. The relative values for miR-1 were calculated by the $2^{-\Delta\Delta Ct}$ method. SYBR Green PCR Mix (Aidlab, Beijing, China) was used to analyze Notch2 mRNA expression using qRT-PCR. GAPDH levels were assessed to standardize the expression of Notch2 mRNA levels. The relative value of Notch2 was calculated with the $2^{-\Delta\Delta Ct}$ method. The following primers were used for reverse transcription and qRT-PCR: (1) miR-1-forward 5′-CAGTGCGTGTCGTGGAGT-3′, (2) miR-1-reverse 5′-GGCCTGGAATGTAAAGAAGT-3′, (3) Notch2-forward 5′-GGGACCCTGT-TCATACCCTCT-3′, (4) Notch2-reverse 5′-GGGCCATGCTTACGCTTTCG-3′.

**Cell transfection.** miR-1mimics, miR-1 inhibitor, NC and inhibitor NC were designed and synthesized by GenePharma (Shanghai, China). Solutions were dissolved in DEPC water to reach a final concentration of 20µM. In a six-well plate, approximately $5-6 \times 10^5$ cells in logarithmic growth phase in medium containing serum and double antibody were added to each well. miR-1 mimics, NC and serum-free 1640 medium were added to TE-1 and KYSE410 cells to a final concentration of 50 nM. miR-1 inhibitor, inhibitor NC and serum-free medium were added to TE-1 and KYSE410 cells to a final concentration of 150 nM. For each group, 12µl of HiPerFect transfection reagent was added to the samples. After incubation at room temperature for 5–10 min, the mixture was added to the cells, and the cells were placed in an incubator.

**Cell proliferation assay.** The cell suspension was placed in a 96-well plate with approximately $3-4 \times 10^3$ cells per well. After transfection for 24, 48, or 72 h, 10 µl of Cell Counting Kit-8 (CCK-8, Beyotime, China) reagent was added to each well. The 96-well plate was placed in a 37 °C, 5% CO$_2$ incubator, and the absorbance was measured at 450 nm using a microplate reader after 2h.

**Cell migration and invasion assay.** After transfection for 24h, cells were cultured in serum-free medium for 12 h. The cell concentration was adjusted to $4-5 \times 10^3$/ml. A transwell chamber with 8-µm pores (Corning, Corning, NY, USA) was used for the 24-well plates. RPMI-1640 medium (500µl) containing 10% FBS was placed in the lower layer, and 200 µl of the cell suspension was placed in the upper chamber. Then, the cells were incubated for 10h. The cells on the lower surface of the chamber were fixed with glacial acetic acid for 15–30 min and stained with crystal violet for 30 min, and 10 fields were selected randomly to count. The cells were covered with Matrigel (BD, Franklin, NJ, USA), and the same method was used to perform cell invasion assays.

**Western blot.** Lysate was used to extract the total protein from the tissues and cells. The protein concentration of each sample was measured and adjusted to a uniform concentration. The protein samples were separated on 10% SDS polyacrylamide gels (SDS-PAGE) and transferred to polyvinylidene fluoride membranes at 100 V for 2.5h. The membrane was blocked with 5% fat-free milk in TBST and incubated with primary antibodies (Abcam, Cambridge, UK) (anti-Notch2, 1: 500; anti-E-cadherin, 1: 500; anti-Vimentin, 1: 1000; and anti-TGF-β1, 1: 1000).
at 4°C overnight. Then, secondary antibodies (1:5000) were added for 2 h at room temperature. The results were visualized using chemiluminescence (Millipore, MA, USA). Image J software (National Institutes of Health, Bethesda, USA) was used to detect the protein expression levels. GAPDH (1:1000) was used as the control.

**Luciferase reporter assay.** The 3′-UTR sequence of wild-type Notch2 and that of a target-site mutant were amplified by PCR, cloned into a dual-luciferase reporter plasmid (Promega, Madison, WI, USA), and named pGL3-Notch2-3′-UTR-WT (wild-type vector) and pGL3-Notch2-3′-UTR-MUT (mutant vector). TE-1 and KYSE410 cells in logarithmic growth phase were inoculated into 96-well plates at 1.5 x 10^4 cells per well before transfection. TE-1 and KYSE410 cells were co-transfected with the Wt or Mut vector and miR-1 mimics, NC, miR-1 inhibitor, or inhibitor NC using the Attractene Transfection Reagent (Qiagen). The ratio of firefly to Renilla luciferase activity was measured with a dual-luciferase reporter system (Promega, Madison, WI, USA) after transfection for 48 h.

**Statistical analysis.** Statistical analysis was performed using the SPSS 17.0 software. The results are presented as the mean ± SEM. A T-test was used to detect differences between the different groups (ESCC tissue, adjacent normal tissue, ESCC plasma, and healthy volunteer plasma). ANOVA was used to assess miR-1 expression under different clinicopathological features. Pearson analysis was used to assess the relationship between miR-1 expression and the clinicopathological features. The T-test was used to analyze cell experiments. p < 0.05 was considered statistically significant.

**References**

1. Enzinger, P. C. & Mayer, R. J. Esophageal cancer. *The New England journal of medicine* 349, 2241–2252, https://doi.org/10.1056/NEJMoa030610 (2003).

2. Hammond, S. M., Bernstein, E., Beach, D. & Hannon, G. J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila. *Nature* 404, 293–296, https://doi.org/10.1038/35051017 (2000).

3. Martinez, I., Patkaniewska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. *Cell* 110, 563–574 (2002).

4. Friedman, R. C., Farh, K. K., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. *Genome research* 19, 92–105, https://doi.org/10.1101/gr.082701.108 (2009).

5. Ren, Y. et al. MiRNA-638 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3. *Cancer letters* 390, 126–136, https://doi.org/10.1016/j.canlet.2017.01.009 (2017).

6. Wang, C. et al. miR-146a-5p mediates epithelial-mesenchymal transition of oesophageal squamous cell carcinoma via targeting Notch2. *British journal of cancer* 115, 1548–1554, https://doi.org/10.1038/bjc.2016.367 (2016).

7. Bartolome-Izquierdo, N. et al. miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. *Blood* 129, 2408–2419, https://doi.org/10.1182/blood-2016-08-731166 (2017).

8. Koetz-Ploch, L. et al. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. *Pigment cell & melanoma research*. https://doi.org/10.1111/pcmr.12578 (2017).

9. Tang, X. R. et al. MicroRNA-101 inhibits invasion and angiogenesis through targeting ITGA3 and its systemic delivery inhibits lung metastasis in nasopharyngeal carcinoma. *Cell death & disease* 8, https://doi.org/10.1038/cddis.2016.486 (2017).

10. Fu, H. L. et al. Altered miRNA expression is associated with differentiation, invasion, and metastasis of esophageal squamous cell carcinoma (ESCC) in patients from Huaian, China. *Cell biochemistry and biophysics* 67, 657–668, https://doi.org/10.1007/s12013-013-9554-3 (2013).

11. Jiang, S. et al. MiR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MEF, cyclin D1 and CDK4 expression. *International journal of molecular medicine* 38, 113–122, https://doi.org/10.3892/ijmm.2016.2619 (2016).

12. Wu, W. R. et al. Notch2 is a crucial regulator of self-renewal and tumorigenicity in human hepatocellular carcinoma cells. *Oncology reports* 36, 181–188, https://doi.org/10.3892/or.2016.4831 (2016).

13. Liu, Z. Y. et al. Notch Signaling Components: Diverging prognostic Indicators in Lung Adenocarcinoma. *Medicine* 95, e3715, https://doi.org/10.1097/MD.0000000000003715 (2016).

14. Wang, C. et al. Notch2 as a promising prognostic biomarker for oesophageal squamous cell carcinoma. *Scientific reports* 6, 25722, https://doi.org/10.1038/srep25722 (2016).

15. Conne, B., Stutz, A. & Vassalli, J. D. The 3′ untranslated region of messenger RNA: A molecular ‘hotspot’ for pathology? *Nature medicine* 6, 637–641, https://doi.org/10.1038/76211 (2000).

16. Guo, Y. J. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. *Cancer research* 68, 26–33, https://doi.org/10.1158/0008-5472.CAN-06-4418 (2008).

17. Hirajima, S. et al. Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. *British journal of cancer* 108, 1822–1829, https://doi.org/10.1038/bjc.2013.148 (2013).

18. Huang, S. D. et al. MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. *Molecular cancer* 11, 51, https://doi.org/10.1186/1476-4298-11-51 (2012).

19. Takeshita, N. et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for esophageal squamous cell carcinoma. *British journal of cancer* 108, 644–652, https://doi.org/10.1038/bjc.2013.18 (2013).

20. Hummel, R. et al. MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. *World journal of gastroenterology* 20, 14904–14912, https://doi.org/10.3748/wjg.v20.i40.14904 (2014).

21. Han, C., Shen, J. K., Horníček, F., Kan, Q. & Duan, Z. Regulation of miRNA-1 (miR-1) expression in human cancer. *Biochimica et biophysica acta* 860, 227–232, https://doi.org/10.1016/j.bbadis.2016.12.004 (2017).

22. Hudson, R. S. et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. *Nucleic acids research* 40, 3689–3703, https://doi.org/10.1093/nar/gkr1222 (2012).

23. Kojima, S. miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. *British journal of cancer* 106, 405–413, https://doi.org/10.1038/bjc.2011.462 (2012).

24. Shang, A. et al. MiR-13p Suppresses the Proliferation, Invasion and Migration of Bladder Cancer Cells by Up-Regulating SFRP1 Expression. *Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology* 41, 1179–1188, https://doi.org/10.1159/000464379 (2017).

25. Li, C., Zhang, S., Wang, Q. & Zhang, X. Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes. *Oncoarget* https://doi.org/10.18632/oncoarget.14927 (2017).

26. Du, Y. Y. et al. The tumor-suppressive function of miR-1 by targeting LASP1 and TAGLN2 in esophageal squamous cell carcinoma. *Journal of gastroenterology and hepatology* 31, 384–393, https://doi.org/10.1111/jgh.13180 (2016).
27. Minemura, H. et al. Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor. Cancer science 106, 1642–1650, https://doi.org/10.1111/cas.12808 (2015).
28. Wang, X. et al. Downregulation of MicroRNA-1 is Associated with Poor Prognosis in Hepatocellular Carcinoma. Clinical laboratory 61, 1331–1336 (2015).
29. Rigaud, V. O. et al. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. Oncotarget 8, 6994–7002, https://doi.org/10.18632/oncotarget.14355 (2017).
30. Niu, J., Sun, Y., Guo, Q., Niu, D. & Liu, B. miR-1 Inhibits Cell Growth, Migration, and Invasion by Targeting VEGFA in Osteosarcoma Cells. Disease markers 2016, 7068986, https://doi.org/10.1155/2016/7068986 (2016).
31. Hu, T. et al. miR-1 inhibits progression of high-risk papillomavirus-associated human cervical cancer by targeting G6PD. Oncotarget 7, 86103–86116, https://doi.org/10.18632/oncotarget.13344 (2016).
32. Amir, S. et al. Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer. British journal of cancer 114, 1125–1134, https://doi.org/10.1038/bjc.2016.73 (2016).
33. Xiao, H. et al. miR-206 functions as a novel cell cycle regulator and tumor suppressor in clear-cell renal cell carcinoma. Cancer letters 374, 107–116, https://doi.org/10.1016/j.canlet.2016.01.032 (2016).
34. Sarkar, S. et al. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. American journal of cancer research 3, 465–477 (2013).
35. Seok, J. K., Lee, S. H., Kim, M. J. & Lee, Y. M. MicroRNA-382 induced by HIF-1alpha is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog. Nucleic acids research 42, 8062–8072, https://doi.org/10.1093/nar/gku515 (2014).
36. Yao, L. et al. Downregulation of microRNA-1 in esophageal squamous cell carcinoma correlates with an advanced clinical stage and its overexpression inhibits cell migration and invasion. International journal of molecular medicine 35, 1033–1041, https://doi.org/10.3892/ijmm.2015.2094 (2015).
37. Sun, Y. et al. Differential Notch1 and Notch2 expression and frequent activation of Notch signaling in gastric cancers. Archives of pathology & laboratory medicine 135, 451–458, https://doi.org/10.1043/2009-0665-OA.1 (2011).
38. Adamia, S. et al. NOTCH1 pathway plays a tumor suppressive role in bladder cancer. Cancer discovery 4, 1252, https://doi.org/10.1158/2159-8290.CD-RW2014-195 (2014).
39. The NOTCH pathway plays a tumor suppressive role in bladder cancer. Cancer discovery 4, 1252, https://doi.org/10.1158/2159-8290.CD-RW2014-195 (2014).

Acknowledgements
This study was supported by grants from the Taishan Scholars Program of Shandong Province, China [No. ts20120505], the National Natural Science Foundation of China [No. 81530060], Shandong Medicine and Health Science Technology Expansion Plan, China [No. 2017WS069], and Taian Science Technology Expansion Plan, Shandong, China [No. 2017NS0147].

Author Contributions
B.S.L. designed the experiments, supervised the research and reviewed the manuscript. W.Z.L. wrote the manuscript. X.M.C. and S.Z. participated in the introduction and discussion of the manuscript and reviewed the manuscript. W.Z.L. and M.K.L. performed the experiments and analysed data. H.L.S., D.W.Z. and C.C. took photos, edit pictures and typeset. All authors read and approved the manuscript.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018